Next Article in Journal
Impact of Influenza A Virus Shutoff Proteins on Host Immune Responses
Next Article in Special Issue
A Comparison of Vaccine Hesitancy of COVID-19 Vaccination in China and the United States
Previous Article in Journal
Seroprevalence of SARS-CoV-2 Antibodies in Symptomatic Individuals Is Higher than in Persons Who Are at Increased Risk Exposure: The Results of the Single-Center, Prospective, Cross-Sectional Study
Previous Article in Special Issue
Perception of Health, Mistrust, Anxiety, and Indecision in a Group of Italians Vaccinated against COVID-19
 
 
Article

Interim Estimates of COVID-19 Vaccine Effectiveness in a Mass Vaccination Setting: Data from an Italian Province

1
Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy
2
Local Health Unit of Pescara, 65124 Pescara, Italy
*
Author to whom correspondence should be addressed.
Academic Editors: Tiziana Ramaci and Massimiliano Barattucci
Vaccines 2021, 9(6), 628; https://doi.org/10.3390/vaccines9060628
Received: 24 May 2021 / Revised: 7 June 2021 / Accepted: 8 June 2021 / Published: 10 June 2021
(This article belongs to the Special Issue SARS-CoV-2 (COVID-19) Vaccination and Compliance/Hesitancy)
This retrospective cohort study compared the rates of virologically-confirmed SARS-CoV-2 infections, symptomatic or lethal COVID-19 among the residents of the Italian province of Pescara who received one or two doses of COVID-19 vaccines, versus the unvaccinated. The official data of the National Health System were used, and a total of 69,539 vaccinated adults were compared with 175,687 unvaccinated. Among the subjects who received at least one vaccine dose, 85 infections (0.12%), 18 severe and 3 lethal COVID-19 cases were recorded after an average follow-up of 38 days. Among the unvaccinated, the numbers were 6948 (4.00%), 933 (0.53%) and 241 (0.14%), respectively. The serious adverse event reports—yet unconfirmed—were 24 out of 102,394 administered doses. In a Cox model, adjusting for age, gender, and selected comorbidities, the effectiveness of either BNT162b2, ChAdOx1 nCoV-19 or mRNA-1273 vaccines was higher than 95% in preventing infections (mostly due to B.1.1.7 variant), symptomatic or lethal COVID-19. No differences were observed across genders, and among the 691 subjects who received the second dose of vaccine later than the recommended date. Although preliminary, these findings support current immunization policies and may help reducing vaccine hesitancy. View Full-Text
Keywords: COVID-19; SARS-CoV-2; vaccine effectiveness; vaccine hesitancy; cohort study; Italy COVID-19; SARS-CoV-2; vaccine effectiveness; vaccine hesitancy; cohort study; Italy
Show Figures

Figure 1

MDPI and ACS Style

Flacco, M.E.; Soldato, G.; Acuti Martellucci, C.; Carota, R.; Di Luzio, R.; Caponetti, A.; Manzoli, L. Interim Estimates of COVID-19 Vaccine Effectiveness in a Mass Vaccination Setting: Data from an Italian Province. Vaccines 2021, 9, 628. https://doi.org/10.3390/vaccines9060628

AMA Style

Flacco ME, Soldato G, Acuti Martellucci C, Carota R, Di Luzio R, Caponetti A, Manzoli L. Interim Estimates of COVID-19 Vaccine Effectiveness in a Mass Vaccination Setting: Data from an Italian Province. Vaccines. 2021; 9(6):628. https://doi.org/10.3390/vaccines9060628

Chicago/Turabian Style

Flacco, Maria Elena, Graziella Soldato, Cecilia Acuti Martellucci, Roberto Carota, Rossano Di Luzio, Antonio Caponetti, and Lamberto Manzoli. 2021. "Interim Estimates of COVID-19 Vaccine Effectiveness in a Mass Vaccination Setting: Data from an Italian Province" Vaccines 9, no. 6: 628. https://doi.org/10.3390/vaccines9060628

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop